These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 28625691)

  • 1. A Case of Locally Advanced Castration-resistant Prostate Cancer With Remarkable Response to Nivolumab.
    Basnet A; Khullar G; Mehta R; Chittoria N
    Clin Genitourin Cancer; 2017 Oct; 15(5):e881-e884. PubMed ID: 28625691
    [No Abstract]   [Full Text] [Related]  

  • 2. Potential role of rituximab in metastatic castrate-resistant prostate cancer.
    Bindal P; Jalil SA; Holle LM; Clement JM
    J Oncol Pharm Pract; 2019 Sep; 25(6):1509-1511. PubMed ID: 30092742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.
    Yu EY; Duan F; Muzi M; Deng X; Chin BB; Alumkal JJ; Taplin ME; Taub JM; Herman B; Higano CS; Doot RK; Hartfeil D; Febbo PG; Mankoff DA
    J Nucl Med; 2015 Mar; 56(3):354-60. PubMed ID: 25635138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of castrate-resistant prostate cancer in older men.
    Ged Y; Horgan AM
    J Geriatr Oncol; 2016 Mar; 7(2):57-63. PubMed ID: 26907565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer.
    Ceci F; Castellucci P; Nanni C; Fanti S
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2103-2104. PubMed ID: 27557847
    [No Abstract]   [Full Text] [Related]  

  • 6. Leading causes of castration-resistant prostate cancer.
    Lu M; Lu H; Kong Q
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer.
    Parker SJ; Pond GR; Agarwal N; Alex A; Heilbrun ME; Sonpavde G
    Clin Genitourin Cancer; 2017 Feb; 15(1):53-59. PubMed ID: 27338517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Castrate-resistant prostate cancer: therapeutic strategies.
    Harzstark AL; Small EJ
    Expert Opin Pharmacother; 2010 Apr; 11(6):937-45. PubMed ID: 20307219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durable complete remission from castration-resistant prostate cancer with sipuleucel-T after estrogen withdrawal.
    Dorff TB; Wilkins C; Hepgur M; Quinn DI
    Clin Genitourin Cancer; 2014 Apr; 12(2):e55-8. PubMed ID: 24331572
    [No Abstract]   [Full Text] [Related]  

  • 10. Emerging agents for the therapy of advanced prostate cancer.
    Hathaway AR; Baker MK; Sonpavde G
    Future Oncol; 2015; 11(20):2775-87. PubMed ID: 26367474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A near miss for prostate cancer immunotherapy.
    Parker C
    Lancet Oncol; 2014 Jun; 15(7):669-71. PubMed ID: 24831980
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment With Galeterone in an Elderly Man With Castration-Resistant Prostate Cancer: A Case Report.
    McKay RR; Mamlouk K; Montgomery B; Taplin ME
    Clin Genitourin Cancer; 2015 Aug; 13(4):e325-e328. PubMed ID: 25600761
    [No Abstract]   [Full Text] [Related]  

  • 13. Improvement in survival and quality of life with new therapeutic agents in metastatic castration-resistant prostate cancer: comparison among the results.
    Recine F; Ceresoli GL; Baciarello G; Cerbone L; Calabrò F
    Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):400-10. PubMed ID: 26337241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic and prostate-specific antigen response after abiraterone acetate withdrawal: a new clinical scenario for castration-resistant prostate cancer?
    Caffo O; Palermo A; Veccia A; Maines F; Chierichetti F; Galligioni E
    Clin Genitourin Cancer; 2013 Dec; 11(4):e10-4. PubMed ID: 23810439
    [No Abstract]   [Full Text] [Related]  

  • 15. Development of Castration Resistant Prostate Cancer can be Predicted by a DNA Hypermethylation Profile.
    Angulo JC; Andrés G; Ashour N; Sánchez-Chapado M; López JI; Ropero S
    J Urol; 2016 Mar; 195(3):619-26. PubMed ID: 26551297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed?
    Mottet N; Clarke N; De Santis M; Zattoni F; Morote J; Joniau S
    BJU Int; 2015 Mar; 115(3):364-72. PubMed ID: 24628790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate.
    Giacinti S; Carlini P; Roberto M; Bassanelli M; Strigari L; Pavese F; Aschelter AM; Felici A; Valeriani M; Cognetti F; Marchetti P
    Anticancer Drugs; 2017 Jan; 28(1):110-115. PubMed ID: 27763885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer.
    Arrabal-Martín M; Anglada-Curado F; Cózar-Olmo JM; Soler-Martínez J; Moreno-Jiménez J; Castiñeiras-Fernández J; Ledo-Cepero MJ; Beardo-Villar P; Requena-Tapia MJ; Zuluaga-Gómez A;
    Actas Urol Esp; 2014 Jun; 38(5):327-33. PubMed ID: 24342031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of non-metastatic castrate-resistant prostate cancer: A systematic review.
    Loriot Y; Supiot S; Beauval JB; Schlürmann F; Pasticier G; Sargos P; Barthélémy P; Pignot G; Maillet D; Vincendeau S; Gross E; Ploussard G; Timsit MO; Borchiellini D
    Cancer Treat Rev; 2018 Nov; 70():223-231. PubMed ID: 30300771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective evaluation of [
    Schwarzenböck SM; Eiber M; Kundt G; Retz M; Sakretz M; Kurth J; Treiber U; Nawroth R; Rummeny EJ; Gschwend JE; Schwaiger M; Thalgott M; Krause BJ
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2105-2113. PubMed ID: 27317482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.